Literature DB >> 15271974

Prevalence of human herpesvirus-8 salivary shedding in HIV increases with CD4 count.

M Gandhi1, D M Koelle, N Ameli, P Bacchetti, J S Greenspan, M Navazesh, K Anastos, R M Greenblatt.   

Abstract

Human herpesvirus-8 (HHV-8) is the etiologic agent of Kaposi's sarcoma (KS), which occurs in epidemic form in human immunodeficiency virus(HIV)-infected individuals. Saliva is the only mucosal fluid in which infectious HHV-8 has been identified, although factors associated with HHV-8 salivary shedding remain unclear. Our study performed PCR analysis for HHV-8 DNA in saliva (and other body fluids) in 66 HIV- and HHV-8-co-infected women without KS so that we could examine predictors for HHV-8 DNA detection. CD4 count was the most significant predictor of HHV-8 salivary shedding, with increased prevalence of HHV-8 salivary DNA at higher CD4 counts. The odds of salivary HHV8 shedding at CD4 counts > = 350 cells/microL was 63 times the odds of shedding at CD4 < 350 (95%CI, 1.3-3078), with an increase in effect size when the analysis was restricted to those with a CD4 nadir > 200. Analysis of these data suggests an increased potential for HHV-8 transmission early in HIV infection, with implications for HHV-8 prevention.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15271974     DOI: 10.1177/154405910408300811

Source DB:  PubMed          Journal:  J Dent Res        ISSN: 0022-0345            Impact factor:   6.116


  9 in total

Review 1.  Saliva as a diagnostic fluid.

Authors:  Daniel Malamud
Journal:  Dent Clin North Am       Date:  2011-01

2.  Oral and systemic health correlates of HIV-1 shedding in saliva.

Authors:  M Navazesh; R Mulligan; N Kono; S K S Kumar; M Nowicki; M Alves; W J Mack
Journal:  J Dent Res       Date:  2010-07-29       Impact factor: 6.116

3.  High prevalence of multiple human herpesviruses in saliva from human immunodeficiency virus-infected persons in the era of highly active antiretroviral therapy.

Authors:  Craig S Miller; Joseph R Berger; Yunanan Mootoor; Sergei A Avdiushko; Hua Zhu; Richard J Kryscio
Journal:  J Clin Microbiol       Date:  2006-07       Impact factor: 5.948

4.  Valganciclovir for suppression of human herpesvirus-8 replication: a randomized, double-blind, placebo-controlled, crossover trial.

Authors:  Corey Casper; Elizabeth M Krantz; Lawrence Corey; Steven R Kuntz; Jie Wang; Stacy Selke; Shannon Hamilton; Meei-Li Huang; Anna Wald
Journal:  J Infect Dis       Date:  2008-07-01       Impact factor: 5.226

5.  Human herpesvirus 8 seroprevalence among Tobago women and the role of sexual lifestyle behavior.

Authors:  Alicia C McDonald; Camille C Ragin; Frank J Jenkins; Joel Weissfeld; John Wilson; Victor W Wheeler; Jaquie B Wilson; Clareann H Bunker; Emanuela Taioli
Journal:  J Med Virol       Date:  2009-02       Impact factor: 2.327

6.  Oral HHV-8 replication among women in Mombasa, Kenya.

Authors:  Warren Phipps; Misty Saracino; Stacy Selke; Meei-Li Huang; Walter Jaoko; Kishorchandra Mandaliya; Anna Wald; Corey Casper; R Scott McClelland
Journal:  J Med Virol       Date:  2014-04-01       Impact factor: 2.327

7.  Gender differences in clinical presentation and outcomes of epidemic Kaposi sarcoma in Uganda.

Authors:  Warren Phipps; Fred Ssewankambo; Huong Nguyen; Misty Saracino; Anna Wald; Lawrence Corey; Jackson Orem; Andrew Kambugu; Corey Casper
Journal:  PLoS One       Date:  2010-11-12       Impact factor: 3.240

8.  Impact of HIV infection and Kaposi sarcoma on human herpesvirus-8 mucosal replication and dissemination in Uganda.

Authors:  Christine Johnston; Jackson Orem; Fred Okuku; Mary Kalinaki; Misty Saracino; Edward Katongole-Mbidde; Merle Sande; Allan Ronald; Keith McAdam; Meei-Li Huang; Linda Drolette; Stacy Selke; Anna Wald; Lawrence Corey; Corey Casper
Journal:  PLoS One       Date:  2009-01-20       Impact factor: 3.240

9.  Signatures of oral microbiome in HIV-infected individuals with oral Kaposi's sarcoma and cell-associated KSHV DNA.

Authors:  Marion Gruffaz; Tinghe Zhang; Vickie Marshall; Priscila Gonçalves; Ramya Ramaswami; Nazzarena Labo; Denise Whitby; Thomas S Uldrick; Robert Yarchoan; Yufei Huang; Shou-Jiang Gao
Journal:  PLoS Pathog       Date:  2020-01-17       Impact factor: 6.823

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.